JCM, Vol. 13, Pages 2465: Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children

Immunoglobulin A nephropathy represents the most prevalent cause of glomerulonephritis worldwide and may lead to renal failure in a relevant number of cases in both paediatric and adult subjects. Although their pathogenesis is still largely unclear, evidence of immune abnormalities provides the background for the use of immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and antiproliferative and alkylating agents. Unfortunately, these treatments fail to achieve a sustained remission in a significant percentage of affected patients and are burdened by significant toxicities. Recent developments of new biologics, including anti-BAFF/APRIL inhibitors and molecules targeting complement components, offered the opportunity to selectively target immune cell subsets or activation pathways, leading to more effective and safer hypothesis-driven treatments. However, studies testing new biologic agents in IgAN should also consider paediatric populations to address the unique needs of children and close the therapeutic gap between adult and paediatric care.

Apr 23, 2024 - 21:11
 0  116
JCM, Vol. 13, Pages 2465: Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children

JCM, Vol. 13, Pages 2465: Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children

Journal of Clinical Medicine doi: 10.3390/jcm13092465

Authors: Decimo Silvio Chiarenza Enrico Eugenio Verrina Edoardo La Porta Gianluca Caridi Gian Marco Ghiggeri Gabriele Mortari Francesca Lugani Andrea Angeletti Carolina Bigatti

Immunoglobulin A nephropathy represents the most prevalent cause of glomerulonephritis worldwide and may lead to renal failure in a relevant number of cases in both paediatric and adult subjects. Although their pathogenesis is still largely unclear, evidence of immune abnormalities provides the background for the use of immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and antiproliferative and alkylating agents. Unfortunately, these treatments fail to achieve a sustained remission in a significant percentage of affected patients and are burdened by significant toxicities. Recent developments of new biologics, including anti-BAFF/APRIL inhibitors and molecules targeting complement components, offered the opportunity to selectively target immune cell subsets or activation pathways, leading to more effective and safer hypothesis-driven treatments. However, studies testing new biologic agents in IgAN should also consider paediatric populations to address the unique needs of children and close the therapeutic gap between adult and paediatric care.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Lema Kefyalew Studying a Ph.D. in Civil Engineering (Hydraulic Engineering). Studying Master of Project Management (MPM). Graduated with MSc in Civil Engineering (Hydraulic Engineering). Followed a 12 month Software Engineering program at ALX_Africa (Holberton school). Graduated with BA degree in Management. Graduated with BSc degree in Civil Engineering.